title: Self-reported cognitive impairment after breast cancer treatment in young women from the ELIPPSE40 cohort: the long-term impact of chemotherapy.
abstract: Cognitive impairment (CI) is common after cancer treatments, but little is known about the long-term evolution of CI, especially in premenopausal women. Since September 2005, all consecutive women included in the French National Health Insurance Fund registry with a diagnosis of primary breast cancer, aged 18-40 years and living in South Eastern France, were asked to participate in a cohort study, including telephone interviews, medical data, and prescription refills of psychotropic drugs and adjuvant endocrine therapy. At each interview, CI is defined as self-report of frequent memory loss and attention deficits. As of February 2010, 222 women with available medical data had taken part in the 10-, 16-, and 28-month telephone interviews, with CI being reported by 37.4%, 36.5%, and 42.3% of participants, respectively. Tranquilizers' dispensation was associated with CI self-report at all three interviews; chemotherapy was reported only at the 28-month interview. At 28 months, besides chemotherapy and tranquilizer's dispensation, having a low educational level and not being a native French woman were also independently associated with CI. Reports of CI were common in young women and primarily related to psycho-social vulnerabilities and cancer treatment. As they affect quality of life, long-term CI complaints deserve greater consideration.
authors: INSERM, U912 "Economic & Social Sciences, Health Systems & Societies" (SE4S), Marseille, France.
authors: Dominique
authors: D
authors: Rey
authors: Anne-Déborah
authors: AD
authors: Bouhnik
authors: Julien
authors: J
authors: Mancini
authors: Marc-Karim
authors: MK
authors: Bendiane
authors: Valérie
authors: V
authors: Séror
authors: Patrice
authors: P
authors: Viens
mesh_terms: D000293:Adolescent; D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy / Q000523:psychology* / Q000628:therapy*; D003072:Cognition Disorders / Q000175:diagnosis*; D015331:Cohort Studies; D005260:Female; D005602:France; D006801:Humans; D015999:Multivariate Analysis; D011619:Psychotropic Drugs / Q000627:therapeutic use*; D012647:Self-Assessment; D012923:Social Class; D055815:Young Adult
chemical_list: D011619:Psychotropic Drugs